<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2159">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05133050</url>
  </required_header>
  <id_info>
    <org_study_id>XHEC-C-2021-070-2</org_study_id>
    <nct_id>NCT05133050</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants</brief_title>
  <official_title>Safety and Efficacy of Early Angiotensin-converting Enzyme Inhibition in Patients With Alport Syndrome Carrying Pathogenic Heterozygous COL4A3,COL4A4 or COL4A5 Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alport syndrome (AS) is the second most common monogenic cause of end-stage renal failure&#xD;
      (ESRF). AS is caused by variants in the COL4A3, COL4A4, and COL4A5 genes, which encode for&#xD;
      the a3, a4, and a5 chains of type IV collagen. This trial is a prospective, randomized,&#xD;
      controlled and multicenter trial. Mainly to assess the safety and efficacy of ramipril in&#xD;
      Alport syndrome patients with variants of COL4A3/COL4A4/COL4A5.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease progression time</measure>
    <time_frame>Up to 240 weeks</time_frame>
    <description>a) Patients from no proteinuria to microalbuminuria; b) patients from microalbuminuria to dominant proteinuria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>5-year disease progression rate and eGFR slope</measure>
    <time_frame>Up to 240 weeks</time_frame>
    <description>5-year disease progression rate and eGFR slope</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Up to 240 weeks</time_frame>
    <description>Number of patients with adverse events</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">510</enrollment>
  <condition>Alport Syndrome</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Ramipril The initial dose of ramipril is 2.5 mg /d. The blood pressure, blood potassium and blood creatinine is measured every 1-2 weeks. If the blood pressure is normal, the dose of ramipril is adjusted to 5 mg /d after 2 weeks. If the blood pressure is low, the dose of ramipril is reduced to 1.25 mg /d until the blood pressure becomes normal, otherwise, stop ramipril using. If the blood potassium is high (&gt;5.5mmol/L), the dose of ramipril is reduced to 1.25 mg /d until the blood potassium becomes normal, otherwise, stop ramipril using. If the blood creatinine is higher before therapy (â‰¥30%), the dose of ramipril is reduced to 1.25 mg /d until the blood creatinine becomes normal, otherwise, stop ramipril using.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No angiotensin converting enzyme inhibitor (ACEI) and other renin-angiotensin system inhibitors (including angiotensin II receptor antagonists, etc.) treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
    <description>We use ACEI: ramipril, in this prospective, randomized, controlled and multicenter clinical trial to access the safety and efficacy in Alport syndrome patients carried COL4A3/COL4A4/COL4A5 variants.</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 30-50 Years;&#xD;
&#xD;
          2. Sex: All;&#xD;
&#xD;
          3. Alport syndrome patients with variants of COL4A3/COL4A4/COL4A5; hematuria or&#xD;
             microalbuminuria; eGFR&gt;90 mL/min/1.73m2;&#xD;
&#xD;
          4. Patients with microscopic hematuria only;&#xD;
&#xD;
          5. Patients with microscopic hematuria and microalbuminuria: 30-300mg/24h or urine&#xD;
             albumin/creatinine: 30-300mg/g;&#xD;
&#xD;
          6. No angiotensin converting enzyme inhibitor (ACEI) and other renin-angiotensin system&#xD;
             inhibitors (including angiotensin II receptor antagonists, etc.) treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. With primary or secondary kidney disease, including IgA nephropathy, membranous&#xD;
             nephropathy, lupus nephropathy, benign renal arterioles, etc.;&#xD;
&#xD;
          2. Patients with a history of angioedema;&#xD;
&#xD;
          3. Hypovolemia or hypotension (systolic blood pressure less than 90mmHg and/or diastolic&#xD;
             blood pressure less than 60mmHg);&#xD;
&#xD;
          4. Pregnant and lactating women;&#xD;
&#xD;
          5. Patients with bilateral renal artery stenosis or unilateral renal artery stenosis with&#xD;
             solitary kidney;&#xD;
&#xD;
          6. Hyperkalemia, blood potassium&gt;5.5mmol/L;&#xD;
&#xD;
          7. Severe aortic stenosis, severe mitral stenosis;&#xD;
&#xD;
          8. Treatment of drug allergy;&#xD;
&#xD;
          9. Hypertension or other diseases that may require treatment with angiotensin-converting&#xD;
             enzyme inhibitors;&#xD;
&#xD;
         10. Disagree to participate in this research.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gengru Jiang</last_name>
    <phone>+86-13917983703</phone>
    <email>jianggeng-ru@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Gengru Jiang</last_name>
      <phone>+86-13917983703</phone>
      <email>jianggeng-ru@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 27, 2021</study_first_submitted>
  <study_first_submitted_qc>November 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 23, 2021</last_update_submitted>
  <last_update_submitted_qc>November 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis, Hereditary</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramipril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

